The total return over the past 12 months is +40.17% vs. +17.77% for the S&P 500. So far it's up +16.19% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +35.94% | +21.90% | +17.01% | +15.05% | N/A | N/A |
| Total Return CAGR | +40.17% | +26.21% | +21.41% | +19.87% | N/A | N/A |
| Revenue CAGR | +9.50% | +3.45% | +4.59% | +10.20% | +9.52% | N/A |
| Net Income CAGR | (13.25%) | (21.71%) | (6.74%) | (4.00%) | +0.08% | N/A |
| EPS CAGR | (1.25%) | (29.10%) | (2.79%) | (2.80%) | +0.80% | N/A |
| Free Cash Flow CAGR | +35.62% | (3.91%) | +3.24% | +10.67% | +9.56% | N/A |
| Operating Cash Flow CAGR | +29.41% | (4.32%) | +2.62% | +10.14% | +9.35% | N/A |
| Dividends CAGR | +5.81% | +5.16% | +6.81% | +12.50% | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
AbbVie Inc. (ABBV)
| Year | Start Value | End Value | ABBV Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | 1098.86 | 1276.81 | +16.19% | +8.94% | +7.25% |
| 2025 | 825.42 | 1098.86 | +33.13% | +17.72% | +15.41% |
| 2024 | 694.22 | 825.42 | +18.90% | +24.89% | (5.99%) |
| 2023 | 695.80 | 694.22 | (0.23%) | +26.19% | (26.42%) |
| 2022 | 560.95 | 695.80 | +24.04% | (18.17%) | +42.21% |
| 2021 | 423.68 | 560.95 | +32.40% | +28.74% | +3.66% |
| 2020 | 332.01 | 423.68 | +27.61% | +18.37% | +9.24% |
| 2019 | 327.11 | 332.01 | +1.50% | +31.22% | (29.72%) |
| 2018 | 330.35 | 327.11 | (0.98%) | (4.56%) | +3.58% |
| 2017 | 206.30 | 330.35 | +60.13% | +21.70% | +38.43% |
